Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid.

Bjerke, M., Portelius, E., Minthon, L., Wallin, A., Anckarsater, H., Anckarsater, R., Andreasen, N., Zetterberg, H., Andreasson, U., Blennow, K.
Journal   International Journal of Alzheimer's Disease.
Species  
Analytes Measured   Abeta 42
Matrix Tested   Cerebrospinal fluid (CSF)
Year   2010
Volume   2010
Page Numbers  
Application   Alzheimers
Abstract
Background. Patients afflicted with Alzheimer's disease (AD) exhibit a decrease in the cerebrospinal fluid (CSF) concentration of the 42 amino acid form of beta-amyloid (Abeta(42)). However, a high discrepancy between different centers in measured Abeta(42) levels reduces the utility of this biomarker as a diagnostic tool and in monitoring the effect of disease modifying drugs. Preanalytical and analytical confounding factors were examined with respect to their effect on the measured Abeta(42) level. Methods. Aliquots of CSF samples were either treated differently prior to Abeta(42) measurement or analyzed using different commercially available xMAP or ELISA assays. Results. Confounding factors affecting CSF Abeta(42) levels were storage in different types of test tubes, dilution with detergent-containing buffer, plasma contamination, heat treatment, and the origin of the immunoassays used for quantification. Conclusion. In order to conduct multicenter studies, a standardized protocol to minimize preanalytical and analytical confounding factors is warranted.

View Publications

Related Products

R-PLEX Aβ42 (4G8) Antibody Set
Aβ42 (4G8) | Human, Mouse, Rat
R-PLEX Human Aβ42 (6E10) Antibody Set
Aβ42 (6E10) | Human
Neurodegeneration Control Pack 1
Aβ38, Aβ40, Aβ42, Tau (total) | Human, Mouse, Rat
Browse Our Products

By Analytes
By Applications
Search
Customer Service/Orders


Scientific/Technical Support


Instrument Support


Company Headquarters